The “Nature Awards MDx Impact Grants” research program, launched by Seegene and Springer Nature, is a new initiative to develop innovative diagnostic assays. It supports researchers worldwide in developing diagnostic tests using Seegene’s cutting-edge multiplex PCR technology. The global call for research projects builds on the success of the 2023 Open Innovation Program, which received 281 applications from 47 countries, selecting 26. By launching the second phase, Seegene and Springer Nature enable even broader participation and innovation, further committing to the dissemination of molecular diagnostics. The application deadline is December 2, 2024. The first evaluation will be completed in February 2025, followed by an on-site assessment and final consultation. The final awardees will be announced in August 2025, with Nature Awards guiding the submission and evaluation process. Seegene is responsible for the entire… 

At HUAWEI CONNECT 2024, Huawei, together with partners during the Healthcare session titled “Enhancing Inclusivity to Amplify Healthcare Intelligence,” unveiled its “Medical Technology Digitalization 2.0” solution for digitizing medical technology. The solution implements AI-powered diagnosis and intelligent quality control, enabling precision medicine and hierarchical diagnosis and treatment. Medical imaging data accounts for 80% of clinical data. AI is used to fully analyze the value of such data, which is crucial for clinical diagnosis, decision-making, and disease prevention. Huawei’s Medical Technology Digitalization 2.0 solution includes AI, computing, storage, and networks, and collaborates with the innovative applications of industry partners to implement AI-based quality control and diagnosis, thereby significantly improving the quality and efficiency of medical services. To date, this solution has been implemented in projects such as the Fourth People’s Hospital in China’s… 

For his research on novel neuroimplants, Dr. Simon Binder has secured funding of 1.5 million euros for five years from the Carl Zeiss Foundation. Binder will establish the junior research group "Biohybrid Neuroimplants Based on Soft Hydrogel Electrodes" at the University of Freiburg. It is affiliated with the BrainLinks-BrainTools research institutions, the Freiburg Center for Interactive Materials and Bioinspired Technologies (FIT), and the Faculty of Engineering at the University of Freiburg. The researchers are developing an innovative connection between the brain and electronic devices by incorporating specially cultured cells into the neuroimplant. With the help of these cells, the implant is intended to integrate harmoniously into the brain tissue. An important aspect of the research is the development of a new design for electrodes based on soft, gel-like materials. These materials are very similar to natural tissue, which can improve the compatibility and functionality of the implants. "Through the biohybrid approach and the use of